Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024.

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301–13.

Article  PubMed  CAS  Google Scholar 

Torcasio R, Gallo Cantafio ME, Ikeda RK, Ganino L, Viglietto G, Amodio N. Lipid metabolic vulnerabilities of multiple myeloma. Clin Exp Med. 2023;23(7):3373–90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xu G, Huang S, Peng J, Gao X, Li M, Yu S, et al. Targeting lipid metabolism in multiple myeloma cells: rational development of a synergistic strategy with proteasome inhibitors. Br J Pharmacol. 2021;178(23):4741–57.

Article  PubMed  CAS  Google Scholar 

Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139(6):876–88.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Petrusca DN, Lee KP, Galson DL. Role of sphingolipids in multiple myeloma progression, Drug Resistance, and their potential as therapeutic targets. Front Oncol. 2022;12:925807.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Choi T, Choi IY, Han K, Jeong SM, Yoo JE, Rhee SY et al. Lipid level, lipid variability, and risk of multiple myeloma: a Nationwide Population-based study of 3,527,776 subjects. Cancers (Basel). 2021;13(3).

Ponvilawan B, Charoenngam N, Rittiphairoj T, Ungprasert P. Receipt of Statins is Associated with Lower Risk of multiple myeloma: systematic review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20(7):e399–413.

Article  PubMed  Google Scholar 

Zhang P, Liu B. Statin use and the risk of multiple myeloma: a PRISMA-compliant meta-analysis. Ann Hematol. 2020;99(8):1805–12.

Article  PubMed  CAS  Google Scholar 

Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol. 2017;46(6):2078–89.

Article  PubMed  PubMed Central  Google Scholar 

Arsenault BJ. From the garden to the clinic: how mendelian randomization is shaping up atherosclerotic cardiovascular disease prevention strategies. Eur Heart J. 2022;43(42):4447–9.

Article  PubMed  Google Scholar 

Wang Q, Shi Q, Lu J, Wang Z, Hou J. Causal relationships between inflammatory factors and multiple myeloma: a bidirectional mendelian randomization study. Int J Cancer. 2022;151(10):1750–9.

Article  PubMed  CAS  Google Scholar 

Wang Q, Shi Q, Wang Z, Lu J, Hou J. Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma. BMC Med. 2023;21(1):377.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Went M, Cornish AJ, Law PJ, Kinnersley B, van Duin M, Weinhold N, et al. Search for multiple myeloma risk factors using mendelian randomization. Blood Adv. 2020;4(10):2172–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hu L, Charwudzi A, Li Q, Zhu W, Tao Q, Xiong S, et al. Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis. Ann Hematol. 2021;100(4):1003–12.

Article  PubMed  Google Scholar 

Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–83.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Barton AR, Sherman MA, Mukamel RE, Loh PR. Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses. Nat Genet. 2021;53(8):1260–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li Z, Zhang B, Liu Q, Tao Z, Ding L, Guo B, et al. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. EBioMedicine. 2023;90:104543.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li L, Yu Z, Ren J, Niu T. Low cholesterol levels are associated with increasing risk of plasma cell neoplasm: a UK biobank cohort study. Cancer Med. 2023;12(22):20964–75.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kabat GC, Kim MY, Chlebowski RT, Vitolins MZ, Wassertheil-Smoller S, Rohan TE. Serum lipids and risk of obesity-related cancers in postmenopausal women. Cancer Causes Control. 2018;29(1):13–24.

Article  PubMed  Google Scholar 

Nagel G, Stocks T, Spath D, Hjartaker A, Lindkvist B, Hallmans G, et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol. 2012;91(10):1519–31.

Article  PubMed  CAS  Google Scholar 

Pedersen KM, Colak Y, Bojesen SE, Nordestgaard BG. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. J Hematol Oncol. 2020;13(1):129.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ren J, Wu M. Causal effects of genetically determined blood metabolites on multiple myeloma: a mendelian randomization study. Sci Rep. 2023;13(1):18818.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhou X, He R, Hu WX, Luo S, Hu J. Targeting myeloma metabolism: how abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors. Neoplasia. 2024;50:100974.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Faquih TO, van Klinken JB, Li-Gao R, Noordam R, van Heemst D, Boone S, et al. Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways. Liver Int. 2023;43(7):1458–72.

Article  PubMed  CAS  Google Scholar 

Chapman MJ, Orsoni A, Mellett NA, Nguyen A, Robillard P, Shaw JE, et al. Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia. J Lipid Res. 2024;65(2):100494.

Article  PubMed  CAS  Google Scholar 

Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, et al. Efzofitimod for the treatment of pulmonary sarcoidosis. Chest. 2023;163(4):881–90.

Article  PubMed  CAS  Google Scholar 

Irshad R, Tabassum S, Husain M. Aberrant lipid metabolism in Cancer: current status and emerging therapeutic perspectives. Curr Top Med Chem. 2023;23(12):1090–103.

Article  PubMed  CAS  Google Scholar 

Liu X, Xu P, Wang L, Zhang C, Wang M, Ouyang J et al. Cholesterol Levels Provide Prognostic Information in patients with multiple myeloma. Clin Lab. 2020;66(4).

Bao L, Wang YT, Lu MQ, Chu B, Shi L, Gao S, et al. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis. Front Endocrinol (Lausanne). 2023;14:1157969.

Article  PubMed  Google Scholar 

Makris A, Pagkali A, Nikolousis E, Filippatos TD, Agouridis AP. High-density lipoprotein cholesterol and multiple myeloma: a systematic review and meta-analysis. Atheroscler Plus. 2023;54:7–13.

Article  PubMed  PubMed Central  Google Scholar 

Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB, Guan YY. Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol. 2011;670(2–3):356–64.